title: Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma.
abstract: We investigated DNA copy number aberrations in 37 cell lines derived from multiple myelomas (MMs) using comparative genomic hybridization, and 11 (29.7%) showed high-level gain indicative of gene amplification at 1q12-q22. A corresponding transcriptional mapping using oligonucleotide arrays extracted three up-regulated genes (IRTA2, PDZK1, and S100A6) within the smallest region of overlapping in amplifications. Among them PDZK1 showed amplification and consequent overexpression in the MM cell lines. Amplification of PDZK1 was observed in primary cases of MM as well. MM cell lines with amplification of PDZK1 exhibited the resistance to melphalan-, cis-platin-, and vincristin-induced cell death compared with MM cell lines without its amplifications. Furthermore, down-regulation of PDZK1 with an anti-sense oligonucleotide sensitized a cell line KMS-11 to melphalan, cis-platin, and vincristin. Taken together, our results indicate that PDZK1 is likely to be one of targets for 1q12-q22 amplification in MM and may be associated with the malignant phenotype, including drug resistance, in this type of tumor.
authors.affiliation: Department of Molecular Cytogenetics, Medical Research Institute and Graduate School of Biomedical Science, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan.
authors.forename: Jun
authors.initials: J
authors.lastname: Inoue
authors.forename: Takemi
authors.initials: T
authors.lastname: Otsuki
authors.forename: Akira
authors.initials: A
authors.lastname: Hirasawa
authors.forename: Issei
authors.initials: I
authors.lastname: Imoto
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Matsuo
authors.forename: Shiroh
authors.initials: S
authors.lastname: Shimizu
authors.forename: Masafumi
authors.initials: M
authors.lastname: Taniwaki
authors.forename: Johji
authors.initials: J
authors.lastname: Inazawa
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism*; D045744:Cell Line, Tumor; D002874:Chromosome Mapping; D002878:Chromosomes, Human, Pair 1; D002945:Cisplatin / Q000494:pharmacology; D003598:Cytoskeletal Proteins; D015536:Down-Regulation; D018432:Drug Resistance, Multiple / Q000235:genetics*; D005784:Gene Amplification; D018628:Gene Dosage; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008558:Melphalan / Q000494:pharmacology; D008565:Membrane Proteins; D009101:Multiple Myeloma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D020411:Oligonucleotide Array Sequence Analysis; D010641:Phenotype; D012333:RNA, Messenger / Q000032:analysis / Q000378:metabolism; D015854:Up-Regulation; D014750:Vincristine / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D002352:Carrier Proteins; D003598:Cytoskeletal Proteins; D008565:Membrane Proteins; C484659:PDZK1 protein, human; C109245:Pdzk1 protein, rat; D012333:RNA, Messenger; D014750:Vincristine; D002945:Cisplatin; D008558:Melphalan